Alnylam Pharmaceuticals, Inc. ALNY
Revenue Intelligence Report • 45 quarters of SEC filing data • Updated 2026-10-14 • Data through 2026-06-30
Alnylam Pharmaceuticals, Inc. has SEC quarterly revenue data through 2026-06-30. Current, continuous revenue and comparable expense data are insufficient for a spending-based forecast.
Annualized Revenue
$5.16B
SEC Filings
45 quarters
Profile-only page: Current, continuous revenue and comparable expense data are insufficient for a spending-based forecast.
Quarterly Revenue History
| Quarter Ending | Revenue |
|---|---|
| 2009-06-30 | $0.0B |
| 2009-09-30 | $0.0B |
| 2009-12-31 | $0.0B |
| 2010-03-31 | $0.0B |
| 2010-06-30 | $0.0B |
| 2010-09-30 | $0.0B |
| 2010-12-31 | $0.0B |
| 2011-03-31 | $0.0B |
| 2017-03-31 | $0.0B |
| 2017-06-30 | $0.0B |
| 2017-09-30 | $0.0B |
| 2017-12-31 | $0.0B |
| 2018-03-31 | $0.0B |
| 2018-06-30 | $0.0B |
| 2018-09-30 | $0.0B |
| 2018-12-31 | $0.0B |
| 2019-03-31 | $0.0B |
| 2019-06-30 | $0.0B |
| 2019-09-30 | $0.1B |
| 2019-12-31 | $0.1B |
| 2020-03-31 | $0.1B |
| 2020-06-30 | $0.1B |
| 2020-09-30 | $0.1B |
| 2020-12-31 | $0.2B |
| 2021-03-31 | $0.2B |
| 2021-06-30 | $0.2B |
| 2021-09-30 | $0.2B |
| 2021-12-31 | $0.3B |
| 2022-03-31 | $0.2B |
| 2022-06-30 | $0.2B |
| 2022-09-30 | $0.3B |
| 2022-12-31 | $0.3B |
| 2023-03-31 | $0.3B |
| 2023-06-30 | $0.3B |
| 2023-09-30 | $0.8B |
| 2023-12-31 | $0.4B |
| 2024-03-31 | $0.5B |
| 2024-06-30 | $0.7B |
| 2024-09-30 | $0.5B |
| 2024-12-31 | $0.6B |
| 2025-03-31 | $0.6B |
| 2025-06-30 | $0.8B |
| 2025-09-30 | $1.2B |
| 2025-12-31 | $1.1B |
| 2026-06-30 | $1.3B |
Want this analysis for your portfolio?
I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.
Get in Touch